Casirivimab–Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19
Raymund R Razonable, Colin Pawlowski, John C O'horo, Lori L Arndt, Richard Arndt, Dennis M Bierle, Molly Destro Borgen, Sara N Hanson, Michelle C Hedin, Patrick Lenehan, Arjun Puranik, Maria T Seville, Leigh L Speicher, Sidna M Tulledge-Scheitel, A J Venkatakrishnan, Caroline G Wilker, Andrew D Badley, Ravindra Ganesh
EClinicalMedicine, doi:10.1016/j.eclinm.2021.101102
Background: Real-world clinical data to support the use of casirivimabÀimdevimab for the treatment of outpatients with mild to moderate coronavirus disease-19 (COVID-19) is needed. This study aimed to assess the outcomes of casirivimabÀimdevimab treatment of mild to moderate COVID-19. Methods: A retrospective cohort of 696 patients who received casirivimabÀimdevimab between December 4, 2020 and April 9, 2021 was compared to a propensity-matched control of 696 untreated patients with mild to moderate COVID-19 at Mayo Clinic sites in Arizona, Florida, Minnesota, and Wisconsin. Primary outcome was rate of hospitalization at days 14, 21 and 28 after infusion. Findings: The median age of the antibody-treated cohort was 63 years (interquartile range, 52À71); 45¢5% were 65 years old; 51.4% were female. High-risk characteristics were hypertension (52.4%), body mass index 35 (31.0%), diabetes mellitus (24.6%), chronic lung disease (22.1%), chronic renal disease (11.4%), congestive heart failure (6.6%), and compromised immune function (6.7%). Compared to the propensitymatched untreated control, patients who received casirivimabÀimdevimab had significantly lower all-cause hospitalization rates at day 14 (1.3% vs 3.3%; Absolute Difference: 2.0%; 95% confidence interval (CI): 0.5À3.7%), day 21 (1.3% vs 4.2%; Absolute Difference: 2.9%; 95% CI: 1.2À4.7%), and day 28 (1.6% vs 4.8%; Absolute Difference: 3.2%; 95% CI: 1.4À5.1%). Rates of intensive care unit admission and mortality at days 14, 21 and 28 were similarly low for antibody-treated and untreated groups. Interpretation: Among high-risk patients with mild to moderate COVID-19, casirivimabÀimdevimab treatment was associated with a significantly lower rate of hospitalization. Funding: Mayo Clinic.
Funding
Mayo Clinic
Contributors Concept and Design: Razonable, Pawlowski, Ganesh Acquisition, Analysis, or Interpretation of Data: Razonable, Pawlowski, Lenehan, Puranik, Venkatakrishnan, O'Horo, Badley, Ganesh Drafting of the Manuscript:
Supplementary materials Supplementary material associated with this article can be found in the online version at doi:10.1016/j.eclinm.2021.101102.
References
Beigel, Tomashek, Dodd, Remdesivir for the treatment of Covid-19 -final report, N Engl J Med
Bhimraj, Morgan, Schumaker, Infectious diseases society of America guidelines on the treatment and management of patients with COVID-19
Caliendo, Kopeinig, Some practical guidance for the implementation of propensity score matching, J Econ Surv
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Crane, Ganesh, Post, Jacobson, Telemedicine consultations and followup of patients with COVID-19, Mayo Clin Proc
Davidson-Pilon, Kalderstam, Zivich, CamDavidsonPilon/lifelines: v0. 21.3. Zenodo
Ganesh, Salonen, Bhuiyan, Managing patients in the COVID-19 pandemic: a virtual multidisciplinary approach, Mayo Clinic Proc: Innovat, Qual Outcomes
Garcia-Vidal, Cozar-Llisto, Meira, Trends in mortality of hospitalised COVID-19 patients: a single centre observational cohort study from Spain, Lancet Reg Health Eur
Group, Horby, Lim, Dexamethasone in hospitalized patients with Covid-19 -preliminary report, N Engl J Med
Horwitz, Jones, Cerfolio, Trends in COVID-19 risk-adjusted mortality rates, J Hosp Med
Hosmer, Lemeshow, May, Applied survival analysis: regression modeling of time-to-event data
Huang, Yang, Xu, Xu, Liu, Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19, Acta Pharmacol Sin
Nih, Anti, SARS-CoV-2 monoclonal antibodies
O'horo, Cerhan, Cahn, Outcomes of COVID-19 with the mayo clinic model of care and research
Razonable, Aloia, Anderson, A framework for outpatient infusion of anti-spike monoclonal antibodies to high-risk patients with mild to moderate coronavirus disease-19: the mayo clinic model
Richardson, Hirsch, Narasimhan, Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area, JAMA
Tian, Schuemie, Suchard, Evaluating large-scale propensity score performance through real-world and synthetic data experiments, Int J Epidemiol
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet